The Canadian Multicentre CSF Monitoring and Biomarker Study

NACompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Spinal Cord Injury
Interventions
OTHER

Crossover of vasopressors

"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."

Trial Locations (6)

94110

Zuckerberg San Francisco General Hospital (UCSF), San Francisco

V5Z 1M9

Vancouver General Hospital, Vancouver

Unknown

QEII Health Sciences Centre, Halifax

London Health Science Centre- Victoria Campus, London

St. Michael's Hospital, Toronto

Hôpital du Sacré-Coeur, Montreal

All Listed Sponsors
collaborator

Rick Hansen Institute

OTHER

lead

University of British Columbia

OTHER

NCT01279811 - The Canadian Multicentre CSF Monitoring and Biomarker Study | Biotech Hunter | Biotech Hunter